Scholar Rock Holding Corporation (SRRK) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Cambridge, MA, 미국. 현재 CEO는 David L. Hallal.
SRRK 을(를) 보유 IPO 날짜 2018-05-25, 128 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $5.69B.
Scholar Rock Holding Corporation is a biopharmaceutical company focused on discovering and developing medicines that target protein growth factor signaling pathways to treat serious diseases. The company's lead candidate, Apitegromab, a myostatin activation inhibitor, has completed Phase 3 clinical trials for spinal muscular atrophy treatment, while SRK-181 is in Phase 1 development for checkpoint inhibitor-resistant cancers. Scholar Rock maintains a strategic collaboration with Gilead Sciences to develop transforming growth factor beta inhibitors for fibrotic diseases, with a broader pipeline addressing neuromuscular disorders, oncology, and fibrosis indications. Founded in 2012 and headquartered in Cambridge, Massachusetts, the company aims to transform patient outcomes across multiple serious disease areas through its targeted therapeutic approach.
